Katrina F Trivers1, Christina V Watson2, Linda J Neff2, Christopher M Jones3, Karen Hacker4. 1. Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion, CDC, United States. Electronic address: fph1@cdc.gov. 2. Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion, CDC, United States. 3. National Center for Injury Prevention and Control, CDC, United States. 4. National Center for Chronic Disease Prevention and Health Promotion, CDC, United States.
Abstract
INTRODUCTION: During the E-cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) outbreak, patient data on tetrahydrocannabinol (THC)-containing e-cigarette, or vaping, product (EVP) use was collected, but data on non-affected adult product use after the onset of the EVALI outbreak is limited. This study describes adult THC-EVP use after EVALI began. METHODS: THC-EVP use data came from an 18-state web-based panel survey of adult THC- and nicotine-containing EVP users conducted February 2020. Unweighted descriptive statistics were calculated; logistic regression assessed correlates of use. RESULTS: Among 3,980 THC-EVP users, 23.5% used THC-EVPs daily. Common brands of THC-EVPs used were Dank Vapes (47.7%) and Golden Gorilla (38.7%). Reported substances used included THC oils (69.6%), marijuana herb (63.6%) and THC concentrate (46.4%). Access sources included: recreational dispensaries (41.1%), friend/family member (38.6%) and illicit dealers (15.1%). Respondents aged 45-64 years had lower odds for daily use compared with those aged 25-34 years (aOR = 0.73; 95% CI = 0.60, 0.90). Compared with White respondents, Asian respondents had lower odds (aOR = 0.55; 95% CI = 0.36, 0.84) and Black respondents higher odds (aOR = 1.48; 95% CI = 1.17, 1.86) of daily use. Respondents odds of daily use and accessing THC-EVPs through commercial sources were higher among states with legalized nonmedical adult marijuana use compared to states without. CONCLUSIONS: Almost half of respondents reported daily or weekly THC-EVP use, and accessed products through both informal and formal sources, even after EVALI began. Given the potential for future EVALI-like conditions to occur, it is important to monitor the use of THC-EVPs and ensure effective education activities about associated risk. Published by Elsevier Ltd.
INTRODUCTION: During the E-cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) outbreak, patient data on tetrahydrocannabinol (THC)-containing e-cigarette, or vaping, product (EVP) use was collected, but data on non-affected adult product use after the onset of the EVALI outbreak is limited. This study describes adult THC-EVP use after EVALI began. METHODS: THC-EVP use data came from an 18-state web-based panel survey of adult THC- and nicotine-containing EVP users conducted February 2020. Unweighted descriptive statistics were calculated; logistic regression assessed correlates of use. RESULTS: Among 3,980 THC-EVP users, 23.5% used THC-EVPs daily. Common brands of THC-EVPs used were Dank Vapes (47.7%) and Golden Gorilla (38.7%). Reported substances used included THC oils (69.6%), marijuana herb (63.6%) and THC concentrate (46.4%). Access sources included: recreational dispensaries (41.1%), friend/family member (38.6%) and illicit dealers (15.1%). Respondents aged 45-64 years had lower odds for daily use compared with those aged 25-34 years (aOR = 0.73; 95% CI = 0.60, 0.90). Compared with White respondents, Asian respondents had lower odds (aOR = 0.55; 95% CI = 0.36, 0.84) and Black respondents higher odds (aOR = 1.48; 95% CI = 1.17, 1.86) of daily use. Respondents odds of daily use and accessing THC-EVPs through commercial sources were higher among states with legalized nonmedical adult marijuana use compared to states without. CONCLUSIONS: Almost half of respondents reported daily or weekly THC-EVP use, and accessed products through both informal and formal sources, even after EVALI began. Given the potential for future EVALI-like conditions to occur, it is important to monitor the use of THC-EVPs and ensure effective education activities about associated risk. Published by Elsevier Ltd.
Authors: Benjamin C Blount; Mateusz P Karwowski; Peter G Shields; Maria Morel-Espinosa; Liza Valentin-Blasini; Michael Gardner; Martha Braselton; Christina R Brosius; Kevin T Caron; David Chambers; Joseph Corstvet; Elizabeth Cowan; Víctor R De Jesús; Paul Espinosa; Carolina Fernandez; Cory Holder; Zsuzsanna Kuklenyik; Jennifer D Kusovschi; Cody Newman; Gregory B Reis; Jon Rees; Chris Reese; Lalith Silva; Tiffany Seyler; Min-Ae Song; Connie Sosnoff; Carleen R Spitzer; Denise Tevis; Lanqing Wang; Cliff Watson; Mark D Wewers; Baoyun Xia; Douglas T Heitkemper; Isaac Ghinai; Jennifer Layden; Peter Briss; Brian A King; Lisa J Delaney; Christopher M Jones; Grant T Baldwin; Anita Patel; Dana Meaney-Delman; Dale Rose; Vikram Krishnasamy; John R Barr; Jerry Thomas; James L Pirkle Journal: N Engl J Med Date: 2019-12-20 Impact factor: 91.245
Authors: Livia Navon; Christopher M Jones; Isaac Ghinai; Brian A King; Peter A Briss; Karen A Hacker; Jennifer E Layden Journal: MMWR Morb Mortal Wkly Rep Date: 2019-11-15 Impact factor: 17.586
Authors: Isaac Ghinai; Ian W Pray; Livia Navon; Kevin O'Laughlin; Lori Saathoff-Huber; Brooke Hoots; Anne Kimball; Mark W Tenforde; Jennifer R Chevinsky; Mark Layer; Ngozi Ezike; Jonathan Meiman; Jennifer E Layden Journal: MMWR Morb Mortal Wkly Rep Date: 2019-10-04 Impact factor: 17.586
Authors: Katrina F Trivers; Andrea S Gentzke; Elyse Phillips; Michael Tynan; Kristy L Marynak; Gillian L Schauer Journal: Addict Behav Rep Date: 2019-10-17
Authors: Carolina Esquer; Oscar Echeagaray; Fareheh Firouzi; Clarissa Savko; Grant Shain; Pria Bose; Abigail Rieder; Sophie Rokaw; Andrea Witon-Paulo; Natalie Gude; Mark A Sussman Journal: Life Sci Alliance Date: 2021-11-22